

## **Supplementary Figures**




Supplementary Fig. S1 The figure shows the initial onset and the course of RLS in Cases 1 and 2. The patient in Case 1 was slightly nervous, but the dialysis course was stable with HDF. However, RLS developed 1 month after switching from HDF to HD. The dialysis efficiency of HD was increased, and though RLS was alleviated, it was not resolved. Thus, the method was switched to HDF. In Case 2, RLS developed in the 2nd year of dialysis and, thus, primary RLS was suspected. However, high-efficiency HDF was performed and the patient recovered after 1 month of the entire course



**Supplementary Fig. S2** Course at the time of recurrence in Case 2. It is strongly suspected that recurrent RLS was caused by deterioration of the hemodiafiltration MFX-U. Even when the total replacement solution was increased or when postdilution HDF was performed, the removal rate of  $\alpha$ 1-MG did not reach 40%, which caused a delay in RLS resolution. The patient was successfully treated by using FDY-GW with a large pore size. In this patient, the removal rate and amount of  $\alpha$ 1-MG at the time of RLS healing after the initial onset were 41.5% and 248 mg, respectively, and after recurrence were 43.6% and 278 mg, respectively

(50L on-line HDF 4.0h Qb = 250mL/min Qdtotal = 500mL/min)



**Supplementary Fig. S3** The same product from the same brand may differ in efficiency depending on the production date. To detect this difference,  $\alpha$ 1-MG removal rate and Alb leakage should be measured. If the evaluation is only for  $\beta$ 2-MG, all products would show the same efficiency